A Single-Arm, Open-Label, Expanded Access Study of RO5185426 in Patients With Metastatic Melanoma (Genentech #ML25597)

Trial Profile

A Single-Arm, Open-Label, Expanded Access Study of RO5185426 in Patients With Metastatic Melanoma (Genentech #ML25597)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Expanded access
  • Sponsors Roche
  • Most Recent Events

    • 15 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Planned end date added (Mar 2013) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top